生效批准
Spyre Therapeutics(SYRE)04-02 18:05
$Spyre Therapeutics(SYRE)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000807 Act: 33 Size: 1 KB 网页链接
简介：Spyre Therapeutics, Inc.于2013年12月16日从特拉华州有限责任公司转换而来。该公司是一家生物技术公司，旨在通过结合同类最佳的抗体工程、合理的治疗组合以及用于患者选择的精准医疗方法，创造下一代炎症性肠病（IBD）产品。Spyre的产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。
| 今开：40 | 昨收：39.29 |
| 最高：40.49 | 最低：36.62 |
| 涨停价： | 跌停价： |
| 总市值：1505794015 |
Spyre Therapeutics(SYRE)04-02 18:05
$Spyre Therapeutics(SYRE)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000807 Act: 33 Size: 1 KB 网页链接
Spyre Therapeutics(SYRE)04-03 04:45
$Spyre Therapeutics(SYRE)$ ARS Annual Report to Security Holders Accession Number: 0001636282-24-000024 Act: 34 Size: 28 MB 网页链接
Spyre Therapeutics(SYRE)03-27 18:05
$Spyre Therapeutics(SYRE)$ S-1/A [Amend] General form for registration of securities under the Securities Act of 1933 Accession Number: 0001193125-24-077777 Act: 33 Size: 13 MB 网页链接
Spyre Therapeutics(SYRE)04-26 05:05
$Spyre Therapeutics(SYRE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-048457 Size: 14 KB 网页链接
Spyre Therapeutics(SYRE)04-24 06:25
$Spyre Therapeutics(SYRE)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902664-24-003035 Act: 34 Size: 59 KB 网页链接
Spyre Therapeutics(SYRE)04-30 18:15
$Spyre Therapeutics(SYRE)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001192 Act: 33 Size: 1 KB 网页链接
Spyre Therapeutics(SYRE)03-15 04:15
$Spyre Therapeutics(SYRE)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-24-067903 Act: 33 Size: 13 MB 网页链接
Spyre Therapeutics(SYRE)03-20 19:15
$Spyre Therapeutics(SYRE)$ PRE 14A Other preliminary proxy statements Accession Number: 0001636282-24-000018 Act: 34 Size: 2 MB 网页链接
SeekingBiotech03-19 00:35
$Spyre Therapeutics(SYRE)$
SYRE - Spyre Therapeutics , prices $180M private financing
1.8亿美金PIPE融资biotech
自身免疫，a4b7 tl1a il-23
Spyre Therapeutics(SYRE)03-02 05:25
$Spyre Therapeutics(SYRE)$ S-1/A [Amend] General form for registration of securities under the Securities Act of 1933 Accession Number: 0001193125-24-055961 Act: 33 Size: 13 MB 网页链接
SeekingBiotech03-19 00:35
$Spyre Therapeutics(SYRE)$
SYRE - Spyre Therapeutics , prices $180M private financing
1.8亿美金PIPE融资biotech
自身免疫，a4b7 tl1a il-23查看全文
$Spyre Therapeutics(SYRE)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-139363 Act: 33 Size: 799 KB 网页链接
$Spyre Therapeutics(SYRE)$ 8-K Current report, items 1.01, 5.02, 5.03, 5.07, 7.01, and 9.01 Accession Number: 0001193125-24-138893 Act: 34 Size: 273 KB 网页链接
$Spyre Therapeutics(SYRE)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001636282-24-000037 Act: 34 Size: 7 MB 网页链接
$Spyre Therapeutics(SYRE)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001636282-24-000039 Act: 34 Size: 339 KB 网页链接
$Spyre Therapeutics(SYRE)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001192 Act: 33 Size: 1 KB 网页链接
$Spyre Therapeutics(SYRE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-048457 Size: 14 KB 网页链接
$Spyre Therapeutics(SYRE)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-114056 Act: 34 Size: 87 KB 网页链接
$Spyre Therapeutics(SYRE)$ 8-K Current report, items 3.02 and 9.01 Accession Number: 0001193125-24-113954 Act: 34 Size: 199 KB 网页链接
$Spyre Therapeutics(SYRE)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902664-24-003035 Act: 34 Size: 59 KB 网页链接
$Spyre Therapeutics(SYRE)$ S-1 General form for registration of securities under the Securities Act of 1933 Accession Number: 0001193125-24-101185 Act: 33 Size: 13 MB 网页链接